FDA Approves Rexulti For Agitation Associated With Dementia Due To Alzheimer's

The U.S. Food and Drug Administration announced the supplemental approval of Rexulti (brexpiprazole) oral tablets to treat agitation associated with dementia due to Alzheimer's disease.
The U.S. Food and Drug Administration announced the supplemental approval of Rexulti (brexpiprazole) oral tablets to treat agitation associated with dementia due to Alzheimer's disease.

US FDA approves Rexulti as first drug for agitation in Alzheimer's dementia

REXULTI® (Brexpiprazole) FDA Approved for Treating Agitation in Alzheimer's Disease Patients

First FDA Approved Medication for Agitation Associated with Alzheimer's Dementia – Psychiatry Education Forum

JAMA Neurology Publishes Complete Results of Positive Phase 3 Study of REXULTI® (brexpiprazole) for Agitation Associated with Dementia Due to Alzheimer's Disease

REXULTI® (brexpiprazole) For Healthcare Professionals

Rexulti (brexpiprazole) is filed in Japan for Alzheimer's associated agitation - Otsuka - Medical Update Online

FDA Approves First Treatment for Alzheimer's Agitation

A silent struggle: Caregiving for a patient with agitation associated with dementia due to Alzheimer's disease - STAT

FDA Approves Rexulti For Agitation Associated With Dementia Due To Alzheimer's

REXULTI® (brexpiprazole) Agitation associated with dementia due to Alzheimer's disease